Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozoleGianluigi Lunardi, Lucia Del Mastro, Fabio Puglisi et al.|Breast Cancer Research and Treatment|2012Cited by 23
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA studyMarina Elena Cazzaniga, Martina Dester, Mario Airoldi et al.|The Breast|2017Cited by 23
SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 TrialsBenedetta Conte, Lucia Del Mastro, Luca Boni et al.|Clinical Cancer Research|2023Cited by 7
Axillary dissection for low-volume nodal involvement after neoadjuvant therapy in breast cancer: multicentre AXSANA cohort studyThorsten Kuehn, Maggie Banys‐Paluchowski, Nina Ditsch et al.|British journal of surgery|2025Cited by 5
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2– Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA StudiesMarina Elena Cazzaniga, P. Pronzato, Claudio Verusio et al.|Breast Care|2019Cited by 1